Theravance Inc. (NASDAQ: THRX) got a big boost today from a purchase of 10 million additional shares by GlaxoSmithKline plc (NYSE: GSK) at a 7.5% premium to a volume-weighted average share price for the past five trading days thru last Friday. GSK now owns about 26.8% of Theravance, up from Glaxo’s previous stake of 18.3%.
The two companies are working on a new once-a-day drug, Relovair, to treat asthma and chronic obstructive pulmonary disease (COPD). The drug is important to Glaxo as a replacement for its Advair drug which has lost its patent protection in the US and will lose it next year in Europe.
GSK and Theravance are gearing up to file for approval use as a treatment for COPD in the US and Europe for Relovair later this year. Approval for the drug’s use against asthma is also on track for this year, but a US filing may be done later due to the stringency of US rules on once-daily drugs.
Theravance shares are up nearly 16% today at $22.57 in a 52-week range of $12.91-$28.95.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
